You are here: Industry Insights > Tavalisse

News List

Rigel concludes subject enrolment in NIH-sponsored Covid-19 trial pharmaceutical-technology
March 15, 2021
Rigel Pharmaceuticals has concluded patient enrolment in a Phase II clinical trial of its oral spleen tyrosine kinase (SYK) inhibitor, fostamatinib, for treating hospitalised Covid-19 patients.
Rigel Awarded $16.5 Million from U.S. Department of Defense for Phase 3 Clinical Trial of Fostamatinib in COVID-19 Patients prnewswire
February 01, 2021
Rigel Pharmaceuticals, Inc. announced it has been awarded $16.5 million by the U.S. Department of Defense's (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to support Rigel's ongoing Phase 3 ...
Rigel & Kissei Enter Agreement contractpharma
October 30, 2018
Rigel & Kissei Enter Agreement
Rigel Website Shows Erroneous Information that Tavalisse Has Been Approved by the FDA biospace
April 16, 2018
Shares of Rigel Pharmaceuticals shot up about 40 percent during Thursday trading due primarily to an error on the company’s website that claimed its drug candidate Tavalisse had gained approval from the U.S. Food and Drug Administration (FDA).
FDA Accepts Rigel's New Drug Application for Tavalisse for Treatment of Chronic ITP americanpharmaceuticalreview
June 22, 2017
Rigel Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) has filed its New Drug Application (NDA) for the use of Tavalisse (fostamatinib disodium) in patients with chronic or persistent immune thrombocytopenia (ITP).